Glycoprotein 41 (gp41) - Pipeline Review, H1 2018

  • ID: 4515999
  • Drug Pipelines
  • 67 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Amunix Operating Inc
  • InnaVirVax SA
  • Longevity Biotech Inc
  • Mymetics Corp
  • Navigen Inc
  • Osel Inc
  • MORE
Glycoprotein 41 (gp41) - Pipeline Review, H1 2018

Summary:

According to the recently published report 'Glycoprotein 41 (gp41) - Pipeline Review, H1 2018'; Glycoprotein 41 (gp41) pipeline Target constitutes close to 19 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes.

Glycoprotein 41 (gp41) - Gp41 or glycoprotein 41 is a transmembrane protein that contains several sites within its ectodomain that are required for infection of host cells. It is a subunit of the envelope protein complex of retroviruses. The interaction of gp41 fusion peptides with the target cell causes a formation of an intermediate structure which bridges and fuses the viral and host membranes together.

The report 'Glycoprotein 41 (gp41) - Pipeline Review, H1 2018' outlays comprehensive information on the Glycoprotein 41 (gp41) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Glycoprotein 41 (gp41) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2, 1, 6 and 2 respectively.

Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 5 molecules, respectively. Report covers products from therapy areas Infectious Disease which include indications Human Immunodeficiency Virus (HIV) Infections (AIDS).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Glycoprotein 41 (gp41)
  • The report reviews Glycoprotein 41 (gp41) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Glycoprotein 41 (gp41) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Glycoprotein 41 (gp41) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Glycoprotein 41 (gp41) targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Glycoprotein 41 (gp41)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Glycoprotein 41 (gp41) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Amunix Operating Inc
  • InnaVirVax SA
  • Longevity Biotech Inc
  • Mymetics Corp
  • Navigen Inc
  • Osel Inc
  • MORE
Introduction

Report Coverage

Glycoprotein 41 (gp41) - Overview

Glycoprotein 41 (gp41) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Glycoprotein 41 (gp41) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Glycoprotein 41 (gp41) - Companies Involved in Therapeutics Development

Amunix Operating Inc

Frontier Biotechnologies Inc

InnaVirVax SA

Longevity Biotech Inc

Mymetics Corp

Navigen Inc

Osel Inc

Pharis Biotec GmbH

Sanofi Pasteur SA

Glycoprotein 41 (gp41) - Drug Profiles

CPT-31 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DS-007 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Enfuvirtide-XTEN - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FB-006M - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HIV-1 vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LBT-5001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Target GP120 and GP41 for HIV - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MYMV-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MYMV-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Peptides to Inhibit gp41 for HIV-1 Infection - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Inhibit Glycoprotein 41 and Glycoprotein 120 for Infectious Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Target GP120 and Gp41 for HIV-1 Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

STOP-3S - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Inhbit GP41 for HIV Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Inhibit GP120, GP41, Tat, Integrase and Protease for HIV-1 Infection - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VAC-02 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VAC-3S - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VCP-2438 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VIR-576 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Glycoprotein 41 (gp41) - Dormant Products

Glycoprotein 41 (gp41) - Discontinued Products

Glycoprotein 41 (gp41) - Product Development Milestones

Featured News & Press Releases

Sep 18, 2017: Navigen Awarded $4.9MM to Advance its HIV Entry Inhibitor CPT

Sep 13, 2017: Mymetics to Present New Preclinical Data on Thermostable and Cold-Chain Independent Virosome based Vaccines

Jul 26, 2017: Navigen Presents Promising Pre-Clinical Data on CPT31 at the 9th International AIDS Society Conference on HIV Science

Nov 28, 2016: First new HIV vaccine efficacy study in seven years has begun

Oct 20, 2016: Dr. Michael Kay Presents Recent Data on Navigen’s HIV Entry Inhibitor, CPT31, at the 2016 HIVR4P meeting

Sep 19, 2016: Mymetics and Texas Biomedical Research Institute Continue Collaboration on HIV Vaccine Development

Aug 24, 2016: Navigen Awarded $500,000 Grant to Support Depot Formulation of its HIV Drug Candidate

Jun 06, 2016: Frontier Biotech Long-acting HIV-1 Fusion Inhibitor Albuvirtide Meets 48-Week Primary Objective: Interim Results of a Phase 3 Trial

May 20, 2016: InnaVirVax Obtained FDA Authorization for a Phase 2 Clinical Trial with VAC-3S in HIV Functional Cure in the US

May 18, 2016: Large-scale HIV vaccine trial to launch in South Africa

Apr 11, 2016: Mymetics' HIV vaccine candidate confirms promise in preclinical study with Texas Biomed

Jul 30, 2015: Encouraging results of the first clinical study of the VAC-3S vaccine against HIV, for which DIAXONHIT develops a companion diagnostic

Apr 30, 2015: Texas Biomed receives NIH grant to study papillomavirus-based AIDS vaccine

Oct 28, 2014: Amunix and PolyPeptide Enter Into Partnership to Produce XTEN Peptide Conjugates for Evaluation by Third Parties for Pharmaceutical Therapeutics

Jul 23, 2014: Amunix and PolyPeptide Publish Multivalent Antiviral XTEN-Peptide Conjugates in vivo Studies in American Chemical Society's Journal "Bioconjugate Chemistry"

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indication, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Amunix Operating Inc, H1 2018

Pipeline by Frontier Biotechnologies Inc, H1 2018

Pipeline by InnaVirVax SA, H1 2018

Pipeline by Longevity Biotech Inc, H1 2018

Pipeline by Mymetics Corp, H1 2018

Pipeline by Navigen Inc, H1 2018

Pipeline by Osel Inc, H1 2018

Pipeline by Pharis Biotec GmbH, H1 2018

Pipeline by Sanofi Pasteur SA, H1 2018

Dormant Projects, H1 2018

Discontinued Products, H1 2018

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Amunix Operating Inc
  • Frontier Biotechnologies Inc
  • InnaVirVax SA
  • Longevity Biotech Inc
  • Mymetics Corp
  • Navigen Inc
  • Osel Inc
  • Pharis Biotec GmbH
  • Sanofi Pasteur SA
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll